PMID- 28250768
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 1687-8337 (Print)
IS  - 1687-8345 (Electronic)
IS  - 1687-8337 (Linking)
VI  - 2017
DP  - 2017
TI  - The Effect of Sitagliptin on the Regression of Carotid Intima-Media Thickening in 
      Patients with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the Sitagliptin 
      Preventive Study of Intima-Media Thickness Evaluation.
PG  - 1925305
LID - 10.1155/2017/1925305 [doi]
LID - 1925305
AB  - Background. The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on the 
      regression of carotid IMT remains largely unknown. The present study aimed to 
      clarify whether sitagliptin, DPP-4 inhibitor, could regress carotid intima-media 
      thickness (IMT) in insulin-treated patients with type 2 diabetes mellitus (T2DM). 
      Methods. This is an exploratory analysis of a randomized trial in which we 
      investigated the effect of sitagliptin on the progression of carotid IMT in 
      insulin-treated patients with T2DM. Here, we compared the efficacy of sitagliptin 
      treatment on the number of patients who showed regression of carotid IMT of 
      >/=0.10 mm in a post hoc analysis. Results. The percentages of the number of the 
      patients who showed regression of mean-IMT-CCA (28.9% in the sitagliptin group 
      versus 16.4% in the conventional group, P = 0.022) and left max-IMT-CCA (43.0% in 
      the sitagliptin group versus 26.2% in the conventional group, P = 0.007), but not 
      right max-IMT-CCA, were higher in the sitagliptin treatment group compared with 
      those in the non-DPP-4 inhibitor treatment group. In multiple logistic regression 
      analysis, sitagliptin treatment significantly achieved higher target attainment 
      of mean-IMT-CCA >/=0.10 mm and right and left max-IMT-CCA >/=0.10 mm compared to 
      conventional treatment. Conclusions. Our data suggested that DPP-4 inhibitors 
      were associated with the regression of carotid atherosclerosis in insulin-treated 
      T2DM patients. This study has been registered with the University Hospital 
      Medical Information Network Clinical Trials Registry (UMIN000007396).
FAU - Mita, Tomoya
AU  - Mita T
AUID- ORCID: 0000-0002-4401-2965
AD  - Department of Metabolism and Endocrinology, Juntendo University Graduate School 
      of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan.
FAU - Katakami, Naoto
AU  - Katakami N
AD  - Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 
      2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; Department of Metabolism & 
      Atherosclerosis, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, 
      Suita, Osaka 565-0871, Japan.
FAU - Shiraiwa, Toshihiko
AU  - Shiraiwa T
AD  - Shiraiwa Medical Clinic, 4-10-24 Houzenji, Kashiwara, Osaka 582-0005, Japan.
FAU - Yoshii, Hidenori
AU  - Yoshii H
AD  - Department of Medicine, Diabetology & Endocrinology, Juntendo Tokyo Koto 
      Geriatric Medical Center, Shinsuna 3-3-20, Koto-ku, Tokyo 136-0075, Japan.
FAU - Gosho, Masahiko
AU  - Gosho M
AD  - Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, 
      University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
FAU - Shimomura, Iichiro
AU  - Shimomura I
AD  - Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 
      2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Watada, Hirotaka
AU  - Watada H
AD  - Department of Metabolism and Endocrinology, Juntendo University Graduate School 
      of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170117
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC5303575
COIS- Tomoya Mita received research funds from MSD and Takeda Pharma K.K. and has 
      received lecture fees from AstraZeneca K.K., Boehringer Ingelheim, Eli Lilly, 
      Kowa Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., MSD, Ono Pharmaceutical 
      Co., and Takeda Pharmaceutical Co. Naoto Katakami is a staff member of the 
      endowed chair (Department of Metabolism and Atherosclerosis) established by funds 
      from Kowa Pharmaceutical Co. and has received research funds from MSD and lecture 
      fees from Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim, Daiichi 
      Sankyo Inc., Dainippon Sumitomo Pharma Co., Eisai Co., Eli Lilly, Kowa 
      Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Novartis Pharmaceuticals, Novo 
      Nordisk Pharma, Ono Pharmaceutical Co., Otsuka Pharmaceutical, Shionogi & Co., 
      Takeda Pharmaceutical Co., Sanofi-Aventis, and Shionogi & Co. Toshihiko Shiraiwa 
      has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Novo Nordisk 
      Pharma, Novartis Pharmaceuticals, Eli Lilly, Abbott Japan, Takeda Pharmaceutical 
      Co., Sanwa Kagaku Kenkyusho Co. Ltd., Mitsubishi Tanabe Pharma Co., Daiichi 
      Sankyo Inc., Astellas Pharma Inc., Ono Pharmaceutical Co., MSD, Shionogi, Pharma, 
      and Taisho Toyama Pharmaceutical Co. Masahiko Gosho received lecture fees from 
      Novartis and Tiho Pharma K.K., received travel fees from Takeda Pharmaceutical 
      Co., and received manuscript fee from Kowa Co., Ltd. Iichiro Shimomura has 
      received lecture fees from Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., Ono 
      Pharmaceutical Co., Kyowa Hakko Kirin Co., Ltd., Kowa Pharmaceutical Co., Sanofi 
      K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Daiichi Sankyo Co., Takeda Pharma K.K., 
      Mitsubishi Tanabe Pharma Co., Teijin Pharma, Eli Lilly Japan K.K., Nippon 
      Boehringer Ingelheim Co., Novartis Pharma K.K., Novo Nordisk Pharma, Bayer 
      Yakuhin, Pfizer Japan Inc., Bristol-Myers K.K., Mochida Pharmaceutical Co., 
      Shionogi & Co., Taisho Toyama Pharmaceutical Co., and Shionogi & Co. and research 
      funds from Astellas Pharma Inc., AstraZeneca K.K., Eisai Co., MSD K.K., Otsuka 
      Pharmaceutical Co., Ono Pharmaceutical Co., Kaken Pharmaceutical Co., Kissei 
      Pharmaceutical Co., Kyowa Hakko Kirin Co., Ltd., Sanofi K.K., Shionogi & Co., 
      Daiichi Sankyo Co., Dainippon Sumitomo Pharma Co., Takeda Pharma K.K., Mitsubishi 
      Tanabe Pharma Co., Teijin Pharma, Nippon Boehringer Ingelheim Co., Novartis 
      Pharma K.K., Novo Nordisk Pharma, Pfizer Japan Inc., Bristol-Myers K.K., Mochida 
      Pharmaceutical Co., Eli Lilly Japan K.K., Kowa Co., Ltd., Kowa Pharmaceutical 
      Co., and Taisho Toyama Pharmaceutical Co. Hirotaka Watada has received lecture 
      fees from Novo Nordisk, Inc., Eli Lilly and Company, Sanofi, Dainippon Sumitomo 
      Pharma Co., Fujifilm, Bayer Health Care, Kissei Pharmaceutical Company, Mochida 
      Pharmaceutical Company, MSD, Takeda Pharmaceutical Company, Boehringer Ingelheim 
      Pharmaceuticals, Inc., Daiichi-Sankyo, Ono Pharmaceutical Co., Ltd., Novartis 
      Pharmaceuticals Corporation, Mitsubishi Tanabe Pharma Corporation, AstraZeneca 
      LP, Kyowa Hakko Kirin Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Kowa Company 
      Ltd., and Astellas Pharma, Inc., advisory fees from Novo Nordisk, Inc., Mochida 
      Pharma Company, AstraZeneca LP, Kowa Company, Astellas Pharma, Inc., Sanofi, 
      Boehringer Ingelheim Pharmaceuticals, Inc., MSD, Mitsubishi Tanabe Pharma 
      Corporation, Novartis Pharmaceuticals Corporation, Dainippon Sumitomo Pharma Co., 
      Takeda Pharmaceutical Company, Ono Pharmaceutical Co., Pfizer, Inc., and Kowa 
      Company, and research funds from Boehringer Ingelheim, Pfizer, Mochida 
      Pharmaceutical Co., Sanofi-Aventis, Novo Nordisk Pharma, Novartis 
      Pharmaceuticals, Sanwa Kagaku Kenkyusho Co., Ltd., Terumo Corp., Eli Lilly, 
      Mitsubishi Tanabe Pharma, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, 
      Shionogi, Pharma, Dainippon Sumitomo Pharma, Kissei Pharma, and AstraZeneca.
EDAT- 2017/03/03 06:00
MHDA- 2017/03/03 06:01
PMCR- 2017/01/17
CRDT- 2017/03/03 06:00
PHST- 2016/10/01 00:00 [received]
PHST- 2016/11/24 00:00 [accepted]
PHST- 2017/03/03 06:00 [entrez]
PHST- 2017/03/03 06:00 [pubmed]
PHST- 2017/03/03 06:01 [medline]
PHST- 2017/01/17 00:00 [pmc-release]
AID - 10.1155/2017/1925305 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2017;2017:1925305. doi: 10.1155/2017/1925305. Epub 2017 Jan 17.